Zoledronic-Acid-Induced Circulating Level Modifications of Angiogenic Factors, Metalloproteinases and Proinflammatory Cytokines in Metastatic Breast Cancer Patients
G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), F. Cognetti(Sapienza University of Rome), Paolo Carlini(National Cancer Institute), Elisabetta Trento(San Gallicano Hospital), Valentina Bordignon(San Gallicano Hospital), Alessandra Fabi(Agostino Gemelli University Polyclinic), Nello Salesi(Tumori Foundation), Serena Di Cosimo(Fondazione IRCCS Istituto Nazionale dei Tumori), Barbara Di Cocco(Tumori Foundation), Andrea Alimonti(Veneto Institute of Molecular Medicine), Paola Papaldo(Cancer Institute (WIA)), Diana Giannarelli(Agostino Gemelli University Polyclinic), Paola Cordiali Fei(San Gallicano Hospital), Giovanna D’Agosto(San Gallicano Hospital)
Cited by 133
Related Papers
Cellular Senescence: Aging, Cancer, and Injury
|Physiological Reviews|2019|1.3k
Subtle variations in Pten dose determine cancer susceptibility
|Nature Genetics|2010|579
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
|Annals of Oncology|2016|398
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240